# Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

> **NCT03946748** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria (PNH)

## Interventions

- **DRUG:** REGN3918

## Key facts

- **NCT ID:** NCT03946748
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-16
- **Primary completion:** 2021-06-09
- **Final completion:** 2021-06-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03946748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03946748, "Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03946748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*